ProMIS™ Neurosciences, Inc., a clinical-stage biotechnology company committed to addressing neurodegenerative and other misfolded protein diseases, has announced it has successfully secured $175.0 million in new investment capital. This substantial funding round marks a pivotal moment for the company, providing significant resources to advance its therapeutic development programs.
The company's core focus lies in the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of these complex conditions. ProMIS Neurosciences employs its proprietary target discovery engine, EpiSelect™, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. These DSEs are central to the pathology of diseases including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). For a clinical-stage biotechnology firm, securing this level of investment is crucial for sustaining the rigorous and capital-intensive process of drug development, from preclinical research through clinical trials.
ProMIS Neurosciences plans to strategically deploy the newly acquired funds to accelerate its therapeutic pipeline, support ongoing clinical trials, and expand its foundational research initiatives. The capital is expected to significantly bolster the development of its selective therapeutic antibodies, which are designed to precisely target the toxic oligomers implicated in these debilitating conditions. This investment positions ProMIS Neurosciences to further its mission of bringing innovative and targeted treatments to patients, reinforcing its long-term commitment to addressing critical unmet medical needs within the challenging landscape of neurodegenerative diseases and driving future growth.
